Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE trial of EP-104IAR in adults with eosinophilic esophagitis
NL-OMON56323Phase 2Recruiting
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Jun 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of EP-104IAR in eosinophilic esophagitis (EoE), sponsored by Eupraxia Pharmaceuticals Inc. Started Jun 2023; status: recruiting.
02
Drugs
EP-104IAR
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NL-OMON56323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56323.